Drug Discovery - Tropical Diseases Conference 2011Global Challenges for New Drug Discovery Against Tropical Diseases
2011 Drug Discovery - Tropical Diseases conference |
| Chairs | Babu L. Tekwani (University of Mississippi) Dennis Kyle (University of South Florida ) |
|||||||||||||||||||||||||||||||||||||||||||||
| Location(s) |
|
|||||||||||||||||||||||||||||||||||||||||||||
| Date | Sunday December 11 2011 - Thursday December 15 2011 | |||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
| Advertising Opportunities | Please contact us to discuss advertising, exhibition & sponsorship opportunities at the Drug Discovery - Tropical Diseases conference. | |||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
| Synopsis | The tropical parasitic diseases are responsible for staggering morbidity and millions of deaths every year, especially in the tropical regions of the word. Although incidences of these diseases are mostly centered in tropical regions the socioeconomic and public health impacts of tropical parasitic diseases are global. Emergence and spread of drug-resistant and more virulent strains of the parasites have further intensified the problem. Despite of the heavy burden on humanity the tropical parasitic diseases have been mostly ignored in relation to advances in modern drug discovery and only few new antipatasitic drugs have been developed during last several years. Improved global attention with increasing funding opportunities through public and non-profit organizations as well as emergence of public-private partnerships for development of strategies to monitor, treat, control and eliminate neglected tropical parasitic diseases have generated. This conference shall focus on multidisciplinary efforts directed against control, treatments and elimination of neglected parasitic diseases. Scientific sessions will be organized specifically (but not limited to) focusing on (1) Social, economic and community-based programs in neglected tropical infectious diseases (2) Drug Resistance: Monitoring, treatment and containment programs (3) Translational research: from bench-side to bed-side (4) Enriching the drug-discovery pipeline- Structural biology/ Molecular biology and therapeutics; Chemical biology/ Medicinal chemistry and therapeutics and In vitro/in vivo pharmacology and efficacy models. |
|||||||||||||||||||||||||||||||||||||||||||||
| Confirmed oral presentations |
Programme · Talk Titles
Plenary
|
|||||||||||||||||||||||||||||||||||||||||||||
| Abstract submission |
Sorry, but all abstract deadlines have passed.
To secure your place at the conference, register now. |
|||||||||||||||||||||||||||||||||||||||||||||
| See the 2009 programme | ||||||||||||||||||||||||||||||||||||||||||||||
Register now ( ) to secure your place. |
||||||||||||||||||||||||||||||||||||||||||||||
Fees |
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Multiple attendance discount: 3 or more members from the same lab are eligible for a discount. Please contact us. Multiple conference discount: We can offer you a discount if you wish to attend multiple conferences. Please contact us. |
||||||||||||||||||||||||||||||||||||||||||||||
Extras |
|
|||||||||||||||||||||||||||||||||||||||||||||
Flights |
|
|||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
Drug Discovery - Tropical Diseases conference 2011 schedule
Confirmed oral presentations
Adam Renslo (UCSF)
Mechanistic Studies of Trioxolane Action and a New Approach to Antimalarial Combination Therapy
Adegboyega K Oyelere (Georgia Institute of Technology)
Aline Zuma (Universidade Federal do Rio de Janeiro)
Effects of Camptothecin, a Potent Topoisomerase I Inhibitor, in Trypanosoma cruzi, The Aetiological Agent of Chaga’s Disease
Angela I Calderon (Harrison School of Pharmacy, Auburn University)
ULTRAFILTRATION AND LIQUID CHROMATOGRAPHY BASED PLASMODIUM FALCIPARUM THIOREDOXIN REDUCTASE SCREENING FOR LIGANDS FROM PLANTS
Bill Baker (University of South Florida)
Gautam Chaudhuri (Meharry Medical College)
Macrophage PAR1 and calpain 1 as drug targets against leishmaniasis
Harry de-Koning (University of Glasgow)
Hira Nakhasi (CBER/FDA)
Ian Gilbert (University of Dundee)
Jessica Kissinger (University of Georgia)
Jonathan Baell (Walter & Eliza Hall Institute of Medical Research)
Whole organism high throughput screening against Trypanosoma brucei brucei, early hit-to-lead medicinal chemistry, and the Australian consortium for HAT medicinal chemistry
Karin Seifert (London School of Hygiene & Tropical Medicine)
Karl Werbovetz (College of Pharmacy)
Kelly Chibale (University of Cape Town)
Integration of ADME in Medicinal Chemistry Progression of Antiplasmodial Hits
Larry Walker (University of Mississippi)
Lars Gille (Veterinary University Vienna)
Species-Selective Inhibition of Mitochondria from Bovine Heart, Yeast and Leishmania by Synthetic Vitamin E Derivatives
Maria de Nazaré Correia Soeiro (Oswaldo Cruz Institute )
Mike Gelb (Univ of Washington)
Drug Discovery for Chagas and HAT: Lanosterol Demethylase Inhibitors and Phenotypic Hit to Lead
Minu Chaudhuri (Meharry Medical College)
Mitochondrial protein translocase: as a novel drug target for African trypanosomiasis
Muhammad Ilias (University of Mississippi)
Neena Goyal (CSIR-Central Drug Research Institute)
Identification of Inhibitors of Leishmanial Dipeptidylcarboxypeptidase: a novel target for drug discovery
Peter Myler (Biomedical Research Institute)
Phercyles Veiga dos Santos (Universidade Federal do Rio de Janeiro)
TFMDI, an inhibitor of NAD+-dependent histone deacetylases (sirtuins) causes growth arrest and activates autophagic mechanisms of cell death in Trypanosoma cruzi
Robin Leatherbarrow (Imperial College London)
Inhibitors of N-myristoyl transferase as potential therapeutic agents against leishmaniasis and malaria
Ronald Quinn (Eskitis Institute, Griffith University)
Sanjay A Desai (National Institute of Allergy and Infectious Diseases(NIAID))
Thomas Kurz (University of Duesseldorf)
Reverse chain modified Fosmidomycin analogs as potent inhibitors of the antimalarial drug target Dxr (IspC)
Xavier Ding (Medicines for Malaria Venture (MMV)
Zlatko Janeba (Institute of Organic Chemistry and Biochemistry ASCR, v.v.i.)
Acyclic nucleoside phosphonates as potential anti-malarial agents